These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 11776105

  • 41. [A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations].
    Ağca H, Sayıner AA, Sengönül A, Simşek I, Akarsu M.
    Mikrobiyol Bul; 2011 Oct; 45(4):664-76. PubMed ID: 22090297
    [Abstract] [Full Text] [Related]

  • 42. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers.
    Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, Suh DJ, Ko SY, Kim MH, Oh HB.
    J Virol Methods; 2008 Apr; 149(1):76-84. PubMed ID: 18291537
    [Abstract] [Full Text] [Related]

  • 43. [Clinical study of oligonucleotide microarray on monitoring the lamivudine-resistance mutations in hepatitis B virus].
    Song JW, Lin JS, Kong XJ, Liang KH.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jun; 11(6):361-3. PubMed ID: 12837218
    [Abstract] [Full Text] [Related]

  • 44. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF.
    Antivir Chem Chemother; 2001 Jun; 12 Suppl 1():67-71. PubMed ID: 11594691
    [Abstract] [Full Text] [Related]

  • 45. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance.
    Li MW, Hou W, Wo JE, Liu KZ.
    J Zhejiang Univ Sci B; 2005 Jul; 6(7):664-7. PubMed ID: 15973769
    [Abstract] [Full Text] [Related]

  • 46. [Mutations of HBV polymerase gene sequence in lamivudine-resistant chronic hepatitis B patients].
    Wang C, Sun J, Chen JJ, Wang ZH, Hou JL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):729-30. PubMed ID: 18504191
    [Abstract] [Full Text] [Related]

  • 47. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine.
    Ide T, Kumashiro R, Koga Y, Tanaka E, Hino T, Hisamochi A, Murashima S, Ogata K, Tanaka K, Kuwahara R, Sata M.
    Am J Gastroenterol; 2003 Sep; 98(9):2048-51. PubMed ID: 14499786
    [Abstract] [Full Text] [Related]

  • 48. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH.
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [Abstract] [Full Text] [Related]

  • 49. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, Rao AR, Wong J, Sung JJ.
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [Abstract] [Full Text] [Related]

  • 50. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    Natsuizaka M, Hige S, Ono Y, Ogawa K, Nakanishi M, Chuma M, Yoshida S, Asaka M.
    J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
    [Abstract] [Full Text] [Related]

  • 51. [High-flux detection of HBV lamivudine resistant strains by genechip and analysis of mutant hotspots in those strains].
    Li B, Zhou BP, Peng JF, Chen LY, Li LX, Wang ZQ, Wang M, Liu SY, Jiang XL.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Nov; 12(11):673-6. PubMed ID: 15623377
    [Abstract] [Full Text] [Related]

  • 52. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
    Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Kawakami Y, Fujimoto Y, Ochi H, Abe H, Maekawa T, Kawakami H, Yatsuji H, Aisaka Y, Kohno H, Aimitsu S, Chayama K.
    Hepatology; 2007 May; 45(5):1179-86. PubMed ID: 17465002
    [Abstract] [Full Text] [Related]

  • 53. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, Tur-Kaspa R.
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [Abstract] [Full Text] [Related]

  • 54. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
    Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, Buti M.
    J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286
    [Abstract] [Full Text] [Related]

  • 55. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
    Woo HY, Park H, Kim BI, Jeon WK, Cho YK, Kim YJ.
    Antivir Ther; 2007 Dec; 12(1):7-13. PubMed ID: 17503742
    [Abstract] [Full Text] [Related]

  • 56. [Detection of YMDD mutations in hepatitis B virus DNA with the use of allele specific polymerase chain reaction].
    Pichkovskaia VA, Fevraleva IS, Ibragimova MM, Solov'eva TI, Drel' PE, Sudarikov AB.
    Mol Gen Mikrobiol Virusol; 2004 Dec; (1):27-9. PubMed ID: 15025001
    [Abstract] [Full Text] [Related]

  • 57. Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.
    Horiike N, Duong TN, Michitaka K, Joko K, Hiasa Y, Konishi I, Yano M, Onji M.
    J Med Virol; 2007 Jul; 79(7):911-8. PubMed ID: 17516520
    [Abstract] [Full Text] [Related]

  • 58. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG, Song E, Burnett RJ, Mphahlele MJ.
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [Abstract] [Full Text] [Related]

  • 59. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ.
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [Abstract] [Full Text] [Related]

  • 60. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy.
    Akuta N, Suzuki F, Kobayashi M, Matsuda M, Sato J, Takagi K, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2003 Dec; 71(4):504-10. PubMed ID: 14556262
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.